**Foreign Justification Example Language**

**R&R Other Project Information (in ASSIST)**

When you answer **YES** to ***6. Does this project involve activities outside of the United States or partnerships with international collaborators?*** You need to not only indicate which country(ies) you are collaborating with, but you also need to include under **12. Other Attachments, a Foreign Justification**. Thus document must “describe special resources or characteristics of the research project (e.g., human subjects, animals, disease, equipment, and techniques), including the reasons why the facilities or other aspects of the proposed project are more appropriate than a domestic setting. In the body of the text, begin the section with a heading indicating ‘Foreign Justification’ and name the file ‘**Foreign Justification.pdf**’”

The **Foreign Justification** example language can be used when your project involves collaborations with foreign experts that could result in co-authored publications in the future.

**FOREIGN JUSTIFICATION**

This project involves collaborations with six experts from Europe:

1. Dr. X, a computational biophysicist from the Faculty of Medicine in the University of \_\_\_\_\_\_\_\_\_. Drs. [PI] and X have collaborated for the past year applying the methods and \_\_\_\_\_\_\_\_\_. Dr. Y, a postdoc from Dr. X’s group, has worked in Dr. [PI] lab at UC San Diego for six months in 2018 as a visiting scientist funded by the Faculty of Medicine of the University of \_\_\_\_\_\_\_\_\_, studying the \_\_\_\_\_\_\_\_\_. The results of this work formed the basis of a collaborative manuscript currently in preparation. The \_\_\_\_\_\_\_\_\_methods that were developed through this work for \_\_\_\_\_\_\_\_\_ are highly relevant for the present proposal, justifying continuation of this collaboration.
2. Dr. Z, a medicinal chemist at the University of \_\_\_\_\_\_\_\_\_. Dr. Z. is the co-developer of the \_\_\_\_\_\_\_\_\_ (some of which are unpublished) for \_\_\_\_\_\_\_\_\_ efforts in this proposal.
3. Dr. R, a pharmacologist from the \_\_\_\_\_\_\_\_\_. Dr. R’s research is focused on the discovery, design, and development of new drug leads for\_\_\_\_\_\_\_\_\_ and \_\_\_\_\_\_\_\_\_. Her group contributes to the pharmacological characterization of the compounds used for \_\_\_\_\_\_\_\_\_.
4. Dr. S., Division of Medicinal Chemist at \_\_\_\_\_\_\_\_\_. Dr. S has been one of the prominent female leaders in the \_\_\_\_\_\_\_\_\_ and focuses on targeting \_\_\_\_\_\_\_\_\_ with novel nanobody approaches. She will supply nanobodies for our \_\_\_\_\_\_\_\_\_ and functional studies. One of her nanobodies is particularly exciting because it \_\_\_\_\_\_\_\_\_, which will help us to understand \_\_\_\_\_\_\_\_\_.
5. Dr. T, Division of Medicinal Chemist at \_\_\_\_\_\_\_\_\_. Dr. T’s research focus is on structure-based drug design of Division of Medicinal Chemist at \_\_\_\_\_\_\_\_\_. He is supplying us with novel \_\_\_\_\_\_\_\_\_ targeting compounds including a rare example of \_\_\_\_\_\_\_\_\_.
6. Dr. V \_\_\_\_\_\_\_\_\_, a pharmacologist and molecular virologist from the Department of Infection and Immunity at the \_\_\_\_\_\_\_\_\_. Dr. V has been collaborating with us for the past few months to make nanobodies that could facilitate \_\_\_\_\_\_\_\_\_.

The collaborations do not involve any paid effort for any of these foreign collaborators. The use of foreign resources is restricted to the nanobodies provided by Drs. S and V., and the chemical compounds provided by Drs. Z, R, and T for our \_\_\_\_\_\_\_\_\_ studies. These collaborations are anticipated to result in **co-authored publications in the future.**